Clinical efficacy of immunotherapy combined with targeted therapy for postoperative recur-rent hepatocellular carcinoma / 中华消化外科杂志
Chinese Journal of Digestive Surgery
;
(12): 41-44, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-990605
ABSTRACT
Systemic therapy is the preferred treatment option for advanced primary hepatic carcinoma, and the results of clinical study IMbrave150 suggesting the superiority of atezolizumab combined with bevacizumab for the treatment of hepatocellular carcinoma. The authors introduce the clinical experience of one patient with postoperative recurrent primary hepatic carcinoma who was treated with atezolizumab plus bevacizumab followed by radiotherapy. The results reveal that the efficacy as stable disease during immunotherapy combination of targeted therapy and partial response after radiotherapy, and the patient tolerating well with a high quality of life.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Digestive Surgery
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS